Codexis, Inc. (CDXS) Fair Value 2026

CDXS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-28, Codexis, Inc. (CDXS) trades at $1.59. QOC: 6.2/10. Value Trap Risk: 13/100 (SAFE). 1/13 models active.

Key Facts

Ticker
CDXS
Price
$1.59
Quality Score
6.2/10
Value Trap Risk
13/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give CDXS?

1 Intrinsic Value Models vs. Current Price ($1.59)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.74 -53.4%

All Models Active

All 1 models are displayed above.

What Is Codexis, Inc. (CDXS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Codexis, Inc.'s intrinsic value is estimated at $0.74. Trading at its current price of $1.59, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -53.4%.

What Do the Models Say About CDXS?

1 of 13 models are currently active for CDXS. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does CDXS Rank in Biotechnology?

Among 625 Biotechnology stocks, CDXS ranks #123 by Quality of Company score. CirclFi's QOC score of 6.2/10 evaluates 32 fundamental signals. A score of 6.2 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

Codexis, Inc.'s positioning within the Biotechnology segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including first-mover advantage in novel targets — shape both the opportunity set and risk profile.

Is CDXS a Value Trap?

CirclFi's Value Trap algorithm assigns CDXS a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Codexis, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Codexis, Inc. earns a quality score of 6.2/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CDXS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CDXS's 1 active models, average confidence is 32%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Codexis, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

EVMNEvommune, Inc.QOC 6.2LEXXLexaria Bioscience Corp.QOC 6.2XFORX4 Pharmaceuticals, Inc.QOC 6.3CRDFCardiff Oncology, Inc.QOC 6.2NTLAIntellia Therapeutics, Inc.QOC 6.3ATHEAlterity Therapeutics LimitedQOC 6.2CLYMClimb Bio, Inc.QOC 5.1ATXIAvenue Therapeutics, Inc.QOC 4.6CLLSCellectis S.A.QOC 3.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: EVMN · LEXX · XFOR · CRDF · NTLA · ATHE · CLYM · ATXI · CLLS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CDXS?

6 companies across all industries closest to CDXS’s Quality of Company score of 6.2/10.

RHEPRegional Health Properties, Inc.QOC 6.2TFXTeleflex IncorporatedQOC 6.2WVVIWillamette Valley Vineyards, Inc.QOC 6.2ZYBTZhengye Biotechnology Holding LimitedQOC 6.2HIVEHIVE Digital Technologies Ltd.QOC 6.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RHEP · TFX · WVVI · ZYBT · HIVE · NVDA

Where Does CDXS Sit in CirclFi's Biotechnology Rankings?

CDXS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Codexis, Inc.’s Valuation?

What is Codexis, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Codexis, Inc. (CDXS). The Quality of Company score is 6.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CDXS overvalued or undervalued right now?

At $1.59, 0 of 1 active models suggest CDXS may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Codexis, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.2 mean for CDXS?

Codexis, Inc.'s QOC of 6.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on CDXS?

CirclFi analyzes CDXS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is CDXS a value trap in 2026?

Codexis, Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Codexis, Inc. (CDXS) a Quality of Company score of 6.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/CDXS/ · Methodology
Primary sources for this CDXS valuation
  • Financial statements: Codexis, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001200375) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CDXS as of ; valuations recomputed .